US cracks down on antidepressant overuse with bold new reforms
The US Health Secretary, Robert F. Kennedy Jr., has unveiled new measures to cut down on prescriptions for antidepressants. The plan targets selective serotonin reuptake inhibitors (SSRIs), a widely used class of drugs that includes Zoloft, Lexapro, Paxil and Prozac. Officials aim to reduce reliance on these medications while promoting alternative treatments and clearer patient choices. Kennedy issued a 'Dear Colleague' letter urging healthcare providers to prioritise non-drug therapies and improve informed consent. The directive also calls for stronger shared decision-making between doctors and patients. This shift comes as data shows 16.6% of US adults—about one in six—were taking SSRIs in 2026.
The Department of Health and Human Services will assemble a technical expert panel to create clinical guidelines for safely reducing medication use. Meanwhile, the Substance Abuse and Mental Health Services Administration (SAMHSA) plans to release training modules this summer, covering the risks of psychiatric drugs and methods for tapering doses. New financial incentives will support the changes. The Centers for Medicare and Medicaid Services will introduce reimbursements for clinicians who spend time helping patients stop taking medications. The overarching goal is to ensure medications are no longer the automatic first choice but one option among many, with clear pathways to stop when appropriate.
The initiatives seek to lower unnecessary dependence on SSRIs and give patients more control over their treatment. Updated guidelines, training programmes, and payment mechanisms will help clinicians guide patients toward non-drug alternatives. The changes reflect a broader push for transparency and patient-led decisions in mental health care.
